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The general public is increasingly aware of the health benefits associated with 
consumption of omega-3 fatty acids.  While evidence of health benefits continues to 
mount, the underlying science is complex. Omega-3 fatty acids vary in their 
physiological efficacy.  
Consumers are typically unaware of differences in the efficacy of different omega-3 
fatty acids and this lack of knowledge can result in consumers being mislead within the 
marketplace.  There is a need for consumers to be educated about the distinctions 
between omega-3 fatty acids.  In the interim consumers remain at risk of purchasing 
premium fortified products and supplements that will not correspond to their desired 
health outcomes. This paper summarises the current understanding of fatty acid 
physiological metabolism and interaction for the purpose of highlighting this complex 
and multifaceted concern. 
Keywords: omega-3, seafood, fish, consumer, fortification, enrichment, 
supplementation 
Introduction 
Omega-3 long chain polyunsaturated fatty acids (n-3 LC-PUFAs) are currently enjoying 
considerable commercial popularity as a result of consistent findings of health benefits 
associated with their consumption.  The Australian marketplace has seen a proliferation 
of food products fortified with n-3 LC-PUFAs, as well as phenomenal growth in 
pharmaceutical omega-3 supplements.  













Globally, the market for n-3 LC-PUFAs supplements is estimated at over US$700 
million with growth rates of 8% per annum (Clough, 2008).  Australia and Spain are 
regarded as international lead markets for omega-3 products and supplements with 
Australian consumers purported to have one of the highest levels of consumer 
awareness of omega-3 fatty acids in the world (Mellentin, 2008).  Strong growth 
continues in the n-3 LC-PUFA supplement market while n-3 LC-PUFAs fortified food 
products have followed the trend previously demonstrated by food products fortified 
with plant sterols.  Consumer hype and new product proliferation within the mass 
market has settled to provide a niche market; infant formula is an exception where n-3 
LC-PUFAs are virtually a standard category ingredient (Mellentin, 2008).   
Positive health outcomes associated with consumption of n-3 LC-PUFAs have been 
demonstrated in the areas of infant development, cardiovascular disease, platelet 
aggregation, hypertension, hyperlipidemia, cancer, dementia and Alzheimer’s disease, 
depression, and inflammation (McManus, Howieson, & Nicholson, 2009; Riediger, 
Othman, Suh, & Moghadasian, 2009; Ruxton & Derbyshire, 2009).  Increasing tissue 
levels of n-3 LC-PUFA at a population level may reduce the incidence of those chronic 
diseases responsible for the largest portion of the global burden of disease (Hibbeln, 
Nieminen, Blasbalg, Riggs, & Lands, 2006). 
Research into the health benefits associated with n-3 LC-PUFAs does not follow a 
standard protocol.  Variations in aspects of research design such sample size, subject 
characteristics, duration of study, n-3 LC-PUFA dosages and form, plasma 
measurement and analysis influence research results and conclusions.  Researchers have 
found low level n-3 LC-PUFA supplementation in patients receiving ongoing 
cardiovascular treatments did not reduce the rate of cardiovascular events (Kromhout, 













Gitay, & Geleijnse, 2010).  Higher supplementation doses may have produced a 
different conclusion.  Researchers reviewing the influence of n-3 LC-PUFAs on 
mortality, cardiovascular disease and cancer state that adjustment for lifestyle factors 
could be improved in cohort studies (Hooper et al., 2006).  Despite the undisputable 
presence of research papers having mixed polarity, there is a vast and mounting quantity 
of robust research supporting the positive health impact of n-3 LC-PUFAs.  
While there are three n-3 LC-PUFAs commonly found in food, evidence of health 
benefits is predominantly associated with the marine sourced n-3 LC-PUFAs: 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).  Alpha-linoleic acid 
(ALA) is a non marine sourced n-3 LC-PUFA and occurs in seed crops such as canola.  
The strongest associations between n-3 LC-PUFAs and health have been demonstrated 
with DHA intake and more recently with a dietary pattern that includes seafood.  This 
indicates that marine based n-3 LC-PUFAs have a greater positive impact on health than 
non marine sourced n-3 LC-PUFAs.  For instance, a review of the efficacy of n-3 LC-
PUFAs in primary and secondary prevention studies on cardiovascular disease revealed 
that consumption of n-3 LC-PUFAs from fish or fish oil consumption, but not 
consumption of ALA, improved rates of all-cause mortality, cardiac and sudden death 
(Wang et al., 2006). 
Consumers are not aware of the relative efficacy of the alternative n-3 LC-PUFA forms 
from both dietary and supplemental sources.  Efficacy of n-3 LC-PUFAs is influenced 
by n-3 LC-PUFA type; additionally in supplements or fortified foods, efficacy will be 
influenced by the food matrix, processing and storage.   This paper provides an 
overview of the complexity and interaction of n-3 LC-PUFAs in order to highlight the 













enormous potential for consumer misunderstanding in the marketing of omega-3 fatty 
acid fortified food and supplements. 
Omega 3 Fatty Acids 
Naturally occurring lipids are made up of aliphatic monocarboxylic acids (fatty acids).  
Fatty acids are named in the hydrocarbon manner reflecting the length of the carbon 
chain and the number and location of double bonds within the molecule (Nawar, 1985).  
The terminal carboxyl group is designated as carbon number one in the backbone of the 
molecule.  Conversely however, when reference is made to an omega numbered fatty 
acid, the omega number refers to the carbon molecule adjacent to a double bond 
numbered from the methyl end of the molecule.  DHA (22:6 -3) for example, is a 
molecule with a backbone 22 carbon atoms in length and contains 6 double bonds with 
the first double bond occurring on carbon 3 from the methyl end.  Figure 1 displays the 
three omega-3 fatty acids commonly found in food.   
Physiological Interactions 
Despite the structural similarity of n-3 LC-PUFAs, human metabolism and 
physiological function of these fatty acids are divergent.  Humans do not possess the 
enzymes necessary to synthesise ALA and as such ALA is an essential fatty acid in 
human diets (Goyens, Spilker, Zock, Katan, & Mensink, 2006).  The human body can 
however convert ALA into DHA or EPA.  Rates of conversion of ALA to EPA have 
been observed to be as high as 8% while conversion to DHA is very limited (Goyens et 
al., 2006).  The impact of conversion rates becomes clear when comparing the 
equivalency of different n-3 LC-PUFAs. Ingested preformed EPA is equivalent to 
ingested ALA at a ratio of 15:1 (Brenna, Salem Jr, Sinclair, & Cunnane, 2009).  













Investigations involving plasma lipid profiles can be challenging as measurements at 
any one time represent a state of physiological flux at the time of sample collection.  
Research investigating the balance of fatty acids in plasma therefore must be cognisant 
of the dynamic nature of fatty acid balance. Plasma lipid profiles at any one point in 
time are the product of ingested n-3 LC-PUFAs, conversion rates and the PUFA profile 
of the background diet.  
As n-3 LC-PUFAs contain a carbon-carbon double bond between the third and fourth 
carbon from the methyl end of the fatty acid molecule, n-6 and n-9 LC-PUFAs contain a 
double bond on the sixth and ninth carbon respectively.  An antagonistic relationship 
exists between n-3 and n-6 LC-PUFAs with regard to biological status (Brenna et al., 
2009).  Ingested n-3 LC-PUFAs compete with n-6 LC-PUFAs for enzymes essential for 
conversion of ALA to EPA or DHA (Simopoulos, 2008).  Major dietary n-6 LC-PUFAs 
are linoleic acid (LA , 18:2n-6) and arachodinic acid (AA, 20:4n-6).  These PUFAs 
occur naturally in seed oils and are a significant component of the western type dietary 
pattern.  The western diet is estimated to have a ratio of n-6 to n-3 LC-PUFA of 
between 15:1 and 16.7:1 (Simopoulos, 2008).  High dietary levels of LA have been 
found to result in increased tissue AA and reduced tissue n-3 LC-PUFAs as well as 
nervous system alterations (Brenna et al., 2009). Reducing the ratio of n-6 to n-3 LC-
PUFA to 4:1 has been found to decrease to reduce total mortality by 70% in secondary 
prevention of cardiovascular disease; a ratio of 5:1 is beneficial for asthma; 2-3:1 
reduces rheumatoid arthritis inflammation and a ratio of 2.5:1 reduces colorectal cancer 
cell proliferation (Simopoulos, 2008). It is recommended that the ratio of n-6 to n-3 LC-
PUFA not exceed 4:1 (Garg, Wood, Singh, & Moughan, 2006). 













Dietary fatty acid profile and interactions define effective EPA and DHA conversion.  
Researchers estimate that large reductions in dietary n-6 LC-PUFA intake could reduce 
dietary n-3 LC-PUFA requirements by as much as 90% (Hibbeln et al., 2006).  Optimal 
EPA synthesis is noted in diets low in LA and increases in DHA synthesis are observed 
in diets high in ALA (Goyens et al., 2006).  DHA synthesis is ‘extremely limited’ and a 
low LA, high ALA diet will not significantly increase plasma DHA as would a 
moderate intake of seafood or fish oils.  Consumption of seafood remains the only 
demonstrable pathway to significantly increased DHA status.  Exchange of LA for ALA 
to enhance fatty acid plasma profiles is recommended as a less effective option for 
individuals that do not consume seafood (Goyens et al., 2006).   
Individuals differ in their ability to metabolise nutrients and in their genetic 
predisposition to chronic disease.  The fields of nutrigenomics and nutrigenetics 
encompass the influence of diet on the genome and the influence of phenotypical 
genetic differences on individual responses to diet (Mutch, Wahli, & Williamson, 
2005). Genetic information is eminent within the study of chronic disease; increased 
risk of chronic disease can identify individuals that will benefit from preventative 
dietary intervention (Omenn, 2009).       
Over the last 150 years, the human westernised diet has undergone unprecedented rapid 
change.  In evolutionary terms the typical human diet contained an n-6 to n-3 LC-PUFA 
ratio of approximately one (Simopoulos, 2006).  Despite individual genetic differences, 
analysis of international data including apparent dietary intakes and relative risks of 
mortality and morbidity for 38 countries found that the total mortality disease burden 
potentially attributable to deficiency in n-3 LC-PUFAs was 20.8% for males and 31.5% 
for females (Hibbeln et al., 2006); specific conditions attributable to n-3 LC-PUFA 













deficiency were as high as 41.2% (males) and 42.5% (females) for coronary heart 
disease mortality, 28.4% for homicide mortality and 98.5% for major depression. The 
researchers concluded that reduction of n-6 LC-PUFA consumption could reduce the 
dietary requirement for n-3 LC-PUFA to one tenth of its current level. 
Fortification in Food 
Codex Alimentarius defines food fortification or enrichment as the addition of an 
essential nutrient(s) to food that may or may not naturally contain the nutrient in order 
to address a nutrient deficiency within a populace.  Enrichment of foods with n-3 LC-
PUFAs is regarded as a way of increasing dietary intake of these fatty acids in order to 
reduce levels of risk of ‘life-style’ diseases and cardiovascular disease in particular 
(Kolanowski, 2005).  It is necessary for levels of fortification to provide significant 
contributions toward recommended dietary n-3 LC-PUFA intakes within the portion 
size that will be consumed by the individual. 
Efficacy of n-3 LC-PUFAs in fortified foods will depend upon fortification with those 
n-3 LC-PUFA forms that provide the highest level of health benefit.  The health benefits 
associated with marine sourced n-3 LC PUFAs have been widely publicised and are 
likely the motivation for consumer purchase of fortified foods.  Fortification with fish 
oil, EPA or DHA will provide the health benefits consumers expect and greater 
physiological benefit than fortification with ALA.  The quality of fish oil used, type of 
food fortified and the nutrient profile of the food will also influence the physiological 
function of n-3 LC-PUFAs (Kolanowski, 2005).  
A major challenge in the development of enriched food products is presented by the 
multiple acceptance criteria to be achieved despite the addition of an active ingredient: 













product freshness, sensory characteristics, appearance, storage conditions, ease of 
preparation and safety standards (Drusch & Mannino, 2009).  Fish oil is highly 
susceptible to oxidation.  Oxidation of n-3 LC-PUFAs can produce toxic peroxides and 
other by-products and as such it is recommended that well refined and stabilised fish oil 
is sourced for the purpose of food enrichment (Kolanowski, 2005).  Formulation, 
processing, packaging, shelf life and storage conditions of foods fortified with n-3 LC-
PUFAs are critical for both bioavailability and oxidative stability.  The influence of 
these factors is complex and multifaceted. Despite the known influence of temperature 
on oxidation, greater oxidative stability of fish oil fortified energy bars has been 
demonstrated through addition of oil during mixing of the dough rather than coating 
bars after baking (Nielsen and Jacobsen, 2009).  
The form in which the fish oil is added, such as neat, within an emulsion or 
microencapsulated will further influence bioavailability and oxidative stability. 
Emulsification of fish oil prior addition to product matrix and use of modified 
atmosphere packaging increase the oxidate stability of fish oils (Nielsen and Jacobsen, 
2009). Neither technique was as effective at improving oxidative stability as the use of a 
microencapsulated form of fish oil.  
Foods fortified with n-3 LC-PUFAs are thought to have similar bioavailability of fatty 
acids as capsule supplements (Kolanowski, 2005).  Bioequivalence has been 
demonstrated for algal oil DHA delivered in capsules and fortified snack bars 
(Arterburn et al., 2007).  Absorption of EPA and DHA from fortified foods has however 
been observed to occur at a faster rate than absorption from supplement capsules 
(Schram et al., 2007).  Further, the nature of the food matrix will influence the rate of 













absorption; absorption of EPA and DHA from a yoghurt drink has been found to be 
faster than from a fitness bar.  
Supplementation 
Recent research has revealed clear differences in the bioavailability of alternate forms of 
concentrated fish oil (Dyerberg, Madsen, Moller, Aardestrup, & Schmidt, 2010).  Re-
esterified triglyceride forms were identified as having superior bioavailability; free fatty 
acids have moderate bioavailability (comparable to natural fish oils or triglycerides) and 
ethyl esters to have lower bioavailability (Dyerberg et al., 2010).  Further investigations 
have been conducted into the bioavailability of oils within gelatine capsules, 
microencapsulated by spray drying milk protein and gelatine-based compounds and 
multiple shell microencapsulation (Drusch & Mannino, 2009).  Microencapsulated fish 
oil supplements are considered superior though researchers note that supplements 
should be consumed within a diet high in monounsaturated fatty acids and low in n-6 
LC-PUFAs (Garg et al., 2006).  Additionally, supplements should be consumed with a 
meal as absorption of n-3 LC-PUFAs within a food matrix is enhanced.  The presence 
of the food matrix augments the rate of entry into intestinal mucosal cells (Garg et al., 
2006).  
Discussion 
Debate about the role of fortified food and nutrient supplements for human health 
continues amidst emerging scientific knowledge and marketplace reactivity.  The 
advocates of n-3 LC-PUFA enriched foods and supplements accurately note that given 
low metabolic conversion of other dietary n-3 LC-PUFA to DHA, individuals that do 
not consume seafood, muscle or organ meats will not achieve recommended DHA 













intakes or status without fortification or supplementation (Garg et al., 2006).  In 
addition, individuals that are at risk of certain chronic diseases such as cardiovascular 
disease have very high recommended daily doses of  1g of n-3 LC-PUFAs (Garg et al., 
2006).  Without dietary inclusion of n-3 LC-PUFA fortified foods or supplements, these 
individuals would be unlikely to achieve this recommended level of intake. 
Increasingly however, research into positive health outcomes and nutrition is revealing 
the strongest evidence with relation to dietary patterns rather than to individual nutrients 
(Lichtenstein & Russell, 2005).  The use of a whole diet approach is further supported 
by the complexity of nutrient requirements and interactions and the disappointing 
results of many single nutrient interventions (Lichtenstein & Russell, 2005).  The 
nutritional benefit of a diet rich in seafood and oily fish in particular extends beyond n-3 
LC-PUFAs content.  Fish, as a whole food, is an excellent source of lean protein and 
other vitamins and minerals including vitamins A and D, B group vitamins, iron, zinc, 
selenium and iodine (Hostenkamp & Sorensen, 2009).  
Liberal food fortification strategies can change perceptions around what constitutes 
healthy food (Meltzer, Aro, Andersen, Koch, & Alexander, 2003).  Risk analysis of 
food product fortification raises the issue of overweight, obesity and chronic disease in 
the developing world and highlights the need for discussion and regulation arising from 
the possibility that fortification may actually promote consumption of an unhealthy or 
unbalanced diet (Meltzer et al., 2003).  Likewise, consumer confusion about the 
messages conveyed in the promotion of supplements can have a potentially negative 
impact on diet and lifestyle factors and support the need for a food-based diet approach 
to achieve optimal public health outcomes (Lichtenstein & Russell, 2005).  There is an 
obvious exception in the need for targeted supplementation to specific population 













segments eg. Vitamin D and calcium supplements for elderly patients (Lichtenstein & 
Russell, 2005).  
A further cause for concern is self administration of supplements without awareness of 
nutrient or drug interactions.  The cardiovascular benefits associated with EPA and 
DHA are associated with reduced coagulatability of blood; self administration of n-3 
LC-PUFAs by a person taking anticoagulants could result in a bleeding tendency 
(Mason, 2009).  Additionally, the oxidative stability of n-3 LC-PUFAs in supplements 
and fortified foods requires ongoing research. 
There is a clear need for the public to be educated about the relative efficacy of n-3 LC-
PUFAs.  The commercial popularity of n-3 LC-PUFAs has its roots in positive research 
linking EPA and DHA to health benefits.  The greatest health benefit can be obtained 
from consumption of adequate dietary n-3 LC-PUFAs within a food matrix.  The most 
direct, bioavailable, uncomplicated and unadulterated sources of efficacious preformed 
EPA and DHA are fish and seafood.  A 100g serving of sardines provides 0.98-1.7g of 
combined DHA and EPA, herring 1.71-1.78g, and lobster 0.07-0.41g (Kris-Etherton, 
Harris & Appel, 2002). 
Consumers require access to information about the benefits of consuming fish and 
seafood, the relative efficacy of different n-3 LC-PUFAs and the interaction of other 
dietary fatty acids.  Almost half of Australians do not have adequate health literacy to 
understand health information and instructions (Australian Bureau of Statistics, 2006).  
Similar levels have been identified internationally. In the US, 28.7% of parents have 
been identified as having basic or below basic health literacy (Yin et al., 2009); 30% of 
Taiwanese adults have marginal or inadequate health literacy despite over 20% of the 













population possessing tertiary qualifications (Lee, Tsai & Kuo, 2010).  The challenge 
for public health professionals transpires in communication of complicated and 
evolving scientific knowledge with simple and straightforward messages that have 
widespread availability. 
Conclusion 
It is thought that consumers are largely unaware of differences in efficacy of n-3 LC-
PUFAs and may assume that the much publicised health benefits of DHA and EPA may 
apply to other omega 3 and / or omega 6 fatty acids.  Physiological efficacy of alternate 
n-3 LC-PUFAs is different.   
Demonstrable evidence of health benefits associated with consumption of marine 
sourced n-3 LC-PUFAs, DHA and EPA, is strong and continues to mount.  There is a 
need for a straightforward consumer communication strategy to inform consumers that 
consumption of diet that includes moderate levels of seafood is the simplest and best 
way to obtain the health benefits associated with n-3 LC-PUFA consumption.   
Health professionals can reduce the propensity for consumer misinformation by 
communicating the superior efficacy of marine sourced n-3 LC-PUFAs and the 
beneficial role of seafood within a balanced diet.  Foods enriched with n-3 LC-PUFAs 
and supplements can help those individuals that have recommended daily intakes of n-3 
LC-PUFAs that are difficult to meet with diet alone or individuals that do not consume 
seafood.   
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Fig 1.  Nomeclature of Omega 3 Fatty Acids. 
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